Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.48 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.42 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13469125 | 0.88 | MAPT (0.47) | MAPTNPSR1HPGDHTTCDC7 | |
| SCHEMBL8007529 | 0.85 | MAPT (0.44) | CYP4F2CYP4A11MAPTNPSR1HPGD | |
| SCHEMBL12407058 | 0.83 | MAPT (0.43) | MAPTNPSR1HPGDHTTCDC7 | |
| SCHEMBL1401554 | 0.83 | NPSR1 (0.46) | CYP4F2CYP4A11MAPTNPSR1HPGD | |
| SCHEMBL425790 | 0.81 | CES2 (0.53) | MAPTNPSR1HTTCDC7DBF4 | |
| SCHEMBL7839331 | 0.80 | PGK1 (0.42) | MAPTNPSR1HPGDHTTCDC7 | |
| SCHEMBL7907090 | 0.80 | PLA2G4A (0.45) | CYP4F2CYP4A11MAPTNPSR1CDC7 | |
| SCHEMBL6826976 | 0.79 | DAO (0.57) | MAPTHPGDCDC7DBF4ALDH1A1 | |
| SCHEMBL13141281 | 0.79 | MAPT (0.42) | CYP4F2CYP4A11MAPTNPSR1HPGD | |
| SCHEMBL2491602 | 0.78 | PLA2G4A (0.46) | CYP4F2CYP4A11MAPTNPSR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110234656-B | Exonucleotidase inhibitors and methods of use thereof | 卡利泰拉生物科技公司 | 2023-02-28 | — | — | CN | disclosed |
| US-20230002437-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2023-01-05 | — | — | US | disclosed |
| US-11208414-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-11174261-B2 | — | — | 2021-11-16 | — | — | US | disclosed |
| US-11034715-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200223882-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2020-07-16 | — | — | US | disclosed |
| US-20200087310-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2020-03-19 | — | — | US | disclosed |
| US-10570167-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10472364-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| CN-110402249-A | Extracellular nucleotides enzyme inhibitor and its application method | CALITHERA BIOSCIENCES INC | 2019-11-01 | — | — | CN | disclosed |
| WO-2018119284-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | CALITHERA BIOSCIENCES, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018049145-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | CALITHERA BIOSCIENCES, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| US-20180072742-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2018-03-15 | — | — | US | disclosed |
| EP-2050446-B1 | SULFONAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-7973078-B2 | Sulfonamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-7973078-B2 | Sulfonamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20090312328-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090312328-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-12-17 | — | — | US | disclosed |
| EP-2050446-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-04-22 | — | — | EP | disclosed |
| US-6057341-A | USE IN PHARMACEUTICAL COMPOSITIONS FOR HUMAN OR VETERINARY MEDICINE (SKIN, RHEUMATIC RESPIRATORY, CARDIOVASCULAR, AND OPHTHALMOLOGIC DISORDERS), OR IN COSMETIC COMPOSITIONS AS WELL | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2000-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200223882-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | NT5E, ENTPD5, NT5C2 | CYP4F2 1535/4885CYP4A11 1854/4885MAPT 4512/4885 |
| US-11034715-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | CYP4F2 1535/4885CYP4A11 1854/4885MAPT 4512/4885 |
| US-11174261-B2 | — | ENTPD5, NT5E, ENTPD1 | CYP4F2 1743/4885CYP4A11 1951/4885MAPT 4828/4885 |
| US-11208414-B2 | Ectonucleotidase inhibitors and methods of use thereof | ENTPD5, NT5E, ENTPD1 | CYP4F2 1848/4885CYP4A11 2355/4885MAPT 4808/4885 |
| US-20180072742-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | CYP4F2 1535/4885CYP4A11 1854/4885MAPT 4512/4885 |
| US-10472364-B2 | Ectonucleotidase inhibitors and methods of use thereof | ENTPD5, NT5E, ENTPD1 | CYP4F2 1848/4885CYP4A11 2355/4885MAPT 4808/4885 |
| US-20090312328-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | PTGER1, CYSLTR1, PTGER2 | CYP4F2 4382/4885CYP4A11 2072/4885MAPT 4297/4885 |
| US-10570167-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | CYP4F2 1535/4885CYP4A11 1854/4885MAPT 4512/4885 |
| US-20200087310-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | NT5E, ENTPD5, NT5C2 | CYP4F2 1535/4885CYP4A11 1854/4885MAPT 4512/4885 |
| US-20230002437-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | CYP4F2 1535/4885CYP4A11 1854/4885MAPT 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.